The Centers for Disease Control and Prevention (CDC) recommends that NAAT should be performed on at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered but has not yet been established, and for whom the test result would alter case management or TB control activities.
Smear is not performed for urine, stool, or blood specimens.
TB NAAT is not performed on swabs, stool, or blood specimens.
Typically all days.
The specimen is screened for M. tuberculosis complex with a nucleic acid amplification test (TB NAAT). A smear for AFB is performed and the specimen is cultured on solid and liquid media (see AFB7 for more details). Mycobacteria or partially acid fast organisms are identified to the full extent possible, such as to the species or subspecies level (AFB4).
Infectious Disease, Mycobacteriology
NAAT with AFB3, NAAT with AFB7 and AFB4, TB rule out, AFB2C, NAAT, culture, smear, identification, nucleic acid amplification testing, reverse hybridization testing.
NAAT is a direct TB test component of AFB1; AFB3 is similar to AFB1, except it is primarily for NTM, since the TB NAAT test is not performed; AFB4 is the identification component of AFB1.
TB NAAT: FDA approved for sputum, validated for some other sources.
AFB7: Reference method, no special licensing required.
AFB4: waiver/single use permit is required for Identification of AFB for NYS isolates
Negative for acid fast bacilli.
This is a test algorithm that includes multiple tests. When it is ordered, TB NAAT, smear and culture are typically performed. If an organism is recovered, a reflex identification test will be ordered. The identification method used will depend on the organism.